Can Psychiatric Nurse Practitioners Prescribe Testosterone For Depression?

Viewing This Video Is A Member Exclusive Feature

But you don’t need membership to get Dr. O’Connor’s insight on this topic, it’s in the summary, key takeaways, and related drugs and conditions below.

Want to watch the full video? Join the Health Portal Today.

Join Now

Already a member? Sign In

Timeline

00:00

A psychiatric nurse practitioner asks about helping patients find competent testosterone providers and whether psychiatric clinicians can appropriately evaluate and prescribe testosterone.

01:34

Dr. O’Connor addresses whether testosterone may be prescribed for psychiatric purposes and discusses published evidence supporting testosterone replacement for depressive symptoms in some men with low testosterone.

04:14

Dr. O’Connor discusses clinical evidence involving testosterone gel and depression while recommending conservative therapeutic prescribing supported by data rather than an anti-aging approach.

Video Summary

A psychiatric nurse practitioner asks whether testosterone can be prescribed to men with depression and low testosterone. Dr. O’Connor discusses the regulatory and clinical issues involved in using testosterone for psychiatric symptoms, emphasizing that treatment must be individualized and supported by appropriate evidence, symptoms, laboratory findings, and a strong provider-patient relationship.

The discussion reviews published evidence that testosterone replacement may improve depressive symptoms in some hypogonadal or low-testosterone men. Dr. O’Connor also stresses that testosterone can worsen anxiety or moodiness in susceptible patients and carries additional risks involving natural testosterone suppression, hair loss, erythrocytosis, blood clots, and cardiovascular health.

For clinicians interested in treating these patients, Dr. O’Connor recommends presenting regulators with published medical evidence and framing testosterone as therapeutic care rather than anti-aging medicine. He emphasizes conservative prescribing, careful monitoring, and the ABCDs™ framework when testosterone is used in men with psychiatric symptoms.

Drug Callouts

Testosterone

Testosterone is the central treatment discussed for men who have depressive symptoms along with hypogonadism or low-normal testosterone. Dr. O’Connor explains that some evidence supports improvement in depressive symptoms while cautioning that testosterone can suppress endogenous production and may worsen anxiety or moodiness in susceptible men.

AndroGel

AndroGel is discussed while Dr. O’Connor recalls clinical research evaluating testosterone gel in men with low testosterone and depressive symptoms. He uses this evidence to illustrate that clinicians considering testosterone for psychiatric symptoms should rely on published therapeutic data rather than anti-aging claims.

Condition Callouts

Depression

Depression is the primary psychiatric condition discussed in relation to testosterone treatment. Dr. O’Connor explains that some men with low testosterone and depressive symptoms may improve with testosterone therapy, but psychiatric symptoms, hormone status, and the complete clinical picture must be evaluated individually.

Hypogonadism

Hypogonadism is discussed as an important clinical context for considering testosterone in men with depressive symptoms. Dr. O’Connor emphasizes that treatment decisions should incorporate symptoms and hormone measurements rather than requiring an extremely low total testosterone number in every patient.

Anxiety

Dr. O’Connor cautions that testosterone can worsen anxiety or moodiness in some susceptible men even when it is being considered for depressive symptoms. This makes psychiatric monitoring particularly important when testosterone is prescribed to patients who already have mental health concerns.

Androgen-Induced Erythrocytosis

Increased red blood cell production is discussed as one of the systemic risks clinicians must consider when prescribing testosterone. Dr. O’Connor includes erythrocytosis within the broader ABCDs™ monitoring needed when men receive long-term androgen therapy.

Deep Vein Thrombosis

Deep vein thrombosis is mentioned among the serious clotting complications that clinicians should consider when monitoring men on testosterone. Dr. O’Connor connects thrombotic risk with red blood cell and vascular health rather than treating psychiatric improvement as the only consideration.

Pulmonary Embolism

Pulmonary embolism is discussed as another potentially serious thrombotic complication relevant to men receiving testosterone. Dr. O’Connor emphasizes that clinicians prescribing testosterone for mood or hypogonadal symptoms must also monitor broader cardiovascular and blood-related risks.

Key Takeaways

Published evidence supports considering testosterone therapy for depressive symptoms in selected men who also have low testosterone or hypogonadism.
Psychiatric symptoms should be evaluated individually because testosterone may improve depression in some men while worsening anxiety or moodiness in others.
Testosterone prescribing should be based on symptoms, hormone measurements, medical evidence, and a strong provider-patient relationship rather than one laboratory cutoff.
Clinicians using testosterone for psychiatric patients must also monitor suppression, erythrocytosis, cardiovascular risk, and thrombotic complications.
Dr. O’Connor recommends framing testosterone as evidence-based therapeutic care and harm reduction rather than anti-aging medicine when discussing treatment with regulators.